AKT1 and hepatocellular carcinoma: Moreover, the MDR was a downstream molecular event of EMT, and MK-2206, an AKT-specific inhibitor, in combination with sorafenib significantly reversed the EMT phenotype and P-gp-mediated MDR in sorafenib-resistant HCC cells.